ストックスクリーナーアプリを入手
6.85
2.00%
-0.14
アフターアワーズ：
6.85
前日終値:
$6.99
開ける：
$6.99
24時間の取引高:
5,961
Relative Volume:
0.26
時価総額：
$27.73M
収益：
$6.44M
当期純損益:
$-58.21M
株価収益率:
0.2191
EPS:
31.2684
ネットキャッシュフロー:
$-4.86M
1週間 パフォーマンス:
+0.74%
1か月 パフォーマンス:
-4.06%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$6.85
$7.0721
1週間の範囲:
$6.8201
$7.0721
52週間の値動き範囲:
$6.32
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
Compare KYNB vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
6.85 | 28.30M | 6.44M | -58.21M | -4.86M | 31.27 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-26 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-06-26 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | ダウングレード | Stifel | Buy → Hold |
| 2023-06-26 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | アップグレード | Stifel | Hold → Buy |
| 2023-01-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-09-22 | ダウングレード | Goldman | Neutral → Sell |
| 2021-08-20 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-07-16 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-03-31 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-03-02 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-01 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-26 | 開始されました | Raymond James | Underperform |
| 2020-07-10 | 再開されました | Stifel | Buy |
すべてを表示
Kyntra Bio Inc (KYNB) 最新ニュース
KYNB Stock Price, Quote & Chart | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
KYNB Technical Analysis | Trend, Signals & Chart Patterns | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
Kyntra Bio CEO Thane Wettig buys $19,852 in stock - Investing.com India
Kyntra Bio CEO Thane Wettig buys $19,852 in stock By Investing.com - Investing.com Australia
KYNTRA BIO (KYNB) CEO Thane Wettig adds 2,800 shares in open-market buy - Stock Titan
What's Next for Kyntra Bio (KYNB) at $6.80? 2026-05-19Growth Picks - Newser
Kyntra Bio Rocked by CEO’s Sudden Insider Stock Sale - TipRanks
Kyntra Bio CEO Thane Wettig buys $19,852 in company stock By Investing.com - Investing.com Australia
Kyntra Bio CEO Thane Wettig buys $19,852 in company stock - Investing.com India
KYNTRA BIO (KYNB) CEO Thane Wettig purchases 2,800 shares at $7.09 - Stock Titan
Kyntra Bio (KYNB) Q1 2026 Earnings Transcript - AOL.com
Armistice Capital (FGEN) reports 400,000-share, 9.88% position (May 2026) - Stock Titan
Kyntra Bio (KYNB) Institutional Ownership 2026 - MarketBeat
Number of shareholders of Kyntra Bio, Inc. – NASDAQ:KYNB - TradingView
Number of shareholders of Kyntra Bio, Inc. – LSE:0IL8 - TradingView
Kyntra Bio (Nasdaq: KYNB) Q1 2026 results show higher revenue, ongoing R&D spend - Stock Titan
Kyntra Bio stock (US3156631046): Q1 2026 revenue rises to $3.7M amid pipeline advances - AD HOC NEWS
Kyntra Bio Inc. (KYNB) News, Articles, Events & Latest Updates - Stocktwits
Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances Amidst Challenges - GuruFocus
Kyntra Bio targets Q4 2026 interim readout while extending cash runway into 2028 - MSN
Kyntra Bio (KYNB) reports Q1 loss, tops revenue estimates - MSN
Kyntra Bio, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:KYNB) 2026-05-11 - Seeking Alpha
KYNB: Revenue rose, expenses fell, and clinical milestones remain on track with cash runway into 2028 - TradingView
Is Kyntra Bio (KYNB) 31.3% Overvalued After Q1 2026 Earnings Bea - GuruFocus
KYNB: Revenue up, losses narrowed, and key clinical programs advancing with strong cash position - TradingView
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Kyntra Bio (NASDAQ:KYNB) Q1 Revenue Surges 180% as EPS Miss Tempers After-Hours Gains - ChartMill
Kyntra Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Kyntra Bio: Q1 Earnings Snapshot - 10TV
Kyntra Bio : Reports First Quarter 2026 Financial Results - marketscreener.com
KYNB: Q1 2026 revenue rose to $3.7M, net loss narrowed, and key clinical trials advanced - TradingView
Kyntra Bio (NASDAQ: FGEN) Q1 2026 results, oncology pipeline and cash runway - Stock Titan
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update - Yahoo! Finance Canada
MSN Money - MSN
Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ... By GuruFocus - Investing.com Canada
Kyntra Bio Inc expected to post a loss of $3.35 a shareEarnings Preview - TradingView
Kyntra Bio (KYNB) upgraded to buy: Here's what you should know - MSN
Earnings Preview: Kyntra Bio to Report Financial Results Post-market on May 11 - 富途牛牛
Kyntra Bio sets May 11 Q1 results release, 5 p.m. investor call - Stock Titan
Kyntra Bio to Report First Quarter 2026 Financial Results - GlobeNewswire
Kyntra Bio to report Q1 2026 financial results and host investor call on May 11 - Pluang
William Blair Maintains KYNTRA BIO INC(KYNB.US) With Hold Rating - 富途牛牛
Kyntra Bio Inc (KYNB) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):